tiprankstipranks
BioNxt Solutions Advances MS Drug Studies
Company Announcements

BioNxt Solutions Advances MS Drug Studies

Bionxt Solutions Inc (TSE:BNXT) has released an update.

Don't Miss our Black Friday Offers:

BioNxt Solutions Inc. is moving forward with its Cladribine program for treating multiple sclerosis, progressing to human comparative bioavailability studies in Europe. The company is also conducting a private placement of up to 6 million shares to raise approximately $1.62 million for further research and development. This funding will support their proprietary ODF Cladribine dosage form, aiming to tap into a global MS drug market projected to reach $41 billion by 2033.

For further insights into TSE:BNXT stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskBioNxt Solutions Expands Innovative Drug Delivery Pipeline
TipRanks Canadian Auto-Generated NewsdeskBioNxt Solutions Advances Patent Process for New Drugs
TipRanks Canadian Auto-Generated NewsdeskBioNxt Solutions Expands Patent Protection Globally
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App